The Role of Non-Statin Therapies for LDL-C Lowering for Management of ASCVD Risk
Faculty
OVERVIEW
The Role of Non-Statin Therapies for LDL-C Lowering for Management of ASCVD Risk is organized by PharmCon, Inc. and will be held from Oct 06, 2019 - Dec 14, 2019.
The target audience for this medical event is Nurse, Pharmacist, Pharmacy Technician. This CME Conference has been approved for a maximum of 1 Contact Hours.
A consensus document detailing the management of dyslipidemia with regard to the use of non-statin therapy was recently released in July 2016. New evidence regarding the use of non-statin therapy (i.e., results from IMPROVE IT and HPS2-THRIVE) has been released and new drugs approved (i.e., the PCSK9 inhibitors) since publication of the 2013 ACC/AHA lipid guideline. This has lead to gaps in the guideline regarding clinical decision making surrounding the use of non-statin drugs. It is imperative to disseminate recommendations of this new decision pathway to healthcare practitioners, so that they can provide evidence-based, patient-centered care as members of an interdisciplinary team.
Learning Objectives:
Nurse
• Describe the background of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD)
• Review recommendations from the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of ASCVD Risk
• Recognize the role of non-statin pharmacotherapy in dyslipidemia management
• Identify patient-specific pharmacotherapy plans to optimize outcomes for patients with dyslipidemia
Pharmacist
• Describe the background of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD)
• Review recommendations from the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of ASCVD Risk
• Recognize the role of non-statin pharmacotherapy in dyslipidemia management
• Identify patient-specific pharmacotherapy plans to optimize outcomes for patients with dyslipidemia
Pharmacy Technician
• Describe the background of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD)
• Review recommendations from the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of ASCVD Risk
• Recognize the role of non-statin pharmacotherapy in dyslipidemia management
Additional details will be posted as soon as they are available.
The target audience for this medical event is Nurse, Pharmacist, Pharmacy Technician. This CME Conference has been approved for a maximum of 1 Contact Hours.
A consensus document detailing the management of dyslipidemia with regard to the use of non-statin therapy was recently released in July 2016. New evidence regarding the use of non-statin therapy (i.e., results from IMPROVE IT and HPS2-THRIVE) has been released and new drugs approved (i.e., the PCSK9 inhibitors) since publication of the 2013 ACC/AHA lipid guideline. This has lead to gaps in the guideline regarding clinical decision making surrounding the use of non-statin drugs. It is imperative to disseminate recommendations of this new decision pathway to healthcare practitioners, so that they can provide evidence-based, patient-centered care as members of an interdisciplinary team.
Learning Objectives:
Nurse
• Describe the background of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD)
• Review recommendations from the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of ASCVD Risk
• Recognize the role of non-statin pharmacotherapy in dyslipidemia management
• Identify patient-specific pharmacotherapy plans to optimize outcomes for patients with dyslipidemia
Pharmacist
• Describe the background of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD)
• Review recommendations from the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of ASCVD Risk
• Recognize the role of non-statin pharmacotherapy in dyslipidemia management
• Identify patient-specific pharmacotherapy plans to optimize outcomes for patients with dyslipidemia
Pharmacy Technician
• Describe the background of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD)
• Review recommendations from the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of ASCVD Risk
• Recognize the role of non-statin pharmacotherapy in dyslipidemia management
Additional details will be posted as soon as they are available.
SPECIALITIES
Pharmacy and MedicineRELATED ONLINE COURSES
Text-Based CME
State required course for Alabama ...
2 Contact Hours
May 02, 2021 - Jul 31, 2027 | Text-Based CME
State required course for Alabama ...
1 Contact Hours
Quick Links